SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Prieto M, Berenguer M, Rayón JM, Córdoba J, Argüello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29:250-256.
  • 2
    Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28-S34.
  • 3
    Velidedeoglu E, Mange KC, Frank A, Abt P, Desai NM, Markmann JW, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV− recipients. Transplantation 2004;77:1834-1842.
  • 4
    Berenguer M, Prieto M, San Juan F, Rayón JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
  • 5
    Irish WD, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant 2011;11:1676-1685.
  • 6
    Wiesner RH, Sorrell M, Villamil F; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-S9.
  • 7
    Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009;9:1707-1713.
  • 8
    Filipponi F, Callea F, Salizzoni M, Grazi GL, Fassati LR, Rossi M, et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004;78:1488-1495.
  • 9
    Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int 2005;18:1336-1345.
  • 10
    Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007;84:829-835.
  • 11
    Lladó L, Fabregat J, Castellote J, Ramos E, Xiol X, Torras J, et al.; for THOSIN Study Group. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008;14:1752-1760.
  • 12
    Manousou P, Samonakis D, Cholongitas E, Patch D, O'Beirne J, Dhillon AP, et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009;15:1783-1791.
  • 13
    Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011;17:1394-1403.
  • 14
    Neumann U, Samuel D, Trunečka P, Gugenheim J, Gerunda GE, Friman S. A randomized multicenter study comparing a tacrolimus-based protocol with and without steroids in HCV-positive liver allograft recipients. J Transplant 2012;2012:894215.
  • 15
    Japanese Liver Transplantation Society. Liver transplantation in Japan—registration by the Japanese Liver Transplantation Society [in Japanese]. Ishoku 2010;45:621-631.
  • 16
    Takada Y, Haga H, Ito T, Nabeshima M, Ogawa K, Kasahara M, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006;81:350-354.
  • 17
    Takada Y, Ueda M, Ito T, Sakamoto S, Haga H, Maetani Y, et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl 2006;12:912-919.
  • 18
    Makuuchi M, Belghiti J, Belli G, Fan ST, Lau JW, Ringe B, et al.; for Working Group of the International Scientific Committee of the International Hepato-Pancreato-Biliary Association. IHPBA concordant classification of primary liver cancer: working group report. J Hepatobiliary Pancreat Surg 2003;10:26-30.
  • 19
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
  • 20
    Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, Alter HJ. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000;32:388-393.
  • 21
    Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010;90:661-665.
  • 22
    Takada Y, Uemoto S. Living donor liver transplantation for hepatitis C. Surg Today; doi:10.1007/s00595-012-0361-z.
  • 23
    Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25: 658-663.
  • 24
    Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003;9:S44-S47.
  • 25
    Pirenne J, Aerts R, Koshiba T, Van Gelder F, Roskams T, Schetz M, et al. Steroid-free immunosuppression during and after liver transplantation—a 3-yr follow-up report. Clin Transplant 2003;17:177-182.
  • 26
    Neyts J, Meerbach A, McKenna P, De Clercq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 1996;30:125-132.
  • 27
    Bahra M, Neumann UP, Harren M, Jacob D, Langrehr JM, Berg T, et al. Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage. Transplant Proc 2002;34:2934-2935.
  • 28
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002;8:40-46.
  • 29
    Germani G, Pleguezuelo M, Villamil F, Vaghjiani S, Tsochatzis E, Andreana L, Burroughs AK. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant 2009;9:1725-1731.
  • 30
    Fasola CG, Netto GJ, Christensen LL, Molmenti EP, Sanchez EQ, Levy MF, et al. Delay of hepatitis C recurrence in liver transplant recipients: impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction. Transplant Proc 2002;34:1561-1562.
  • 31
    Ogura Y, Hori T, El Moghazy WM, Yoshizawa A, Oike F, Mori A, et al. Portal pressure <15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl 2010;16:718-728.
  • 32
    Raut V, Mori A, Kaido T, Ogura Y, Taku I, Nagai K, et al. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab. Transplantation 2012;93:99-105.
  • 33
    Jennison C, Turnbull BW. Stochastic curtailment. In: Jennison C, Turnbull BW, eds. Group Sequential Methods With Applications to Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC; 2000:205-220.
  • 34
    San Juan R, Aguado JM, Lumbreras C, Díaz-Pedroche C, López-Medrano F, Lizasoain M, et al.; for RESITRA Network, Spain. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007;7:964-971.
  • 35
    Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-2614.
  • 36
    Segev DL, Sozio SM, Shin EJ, Nazarian SM, Nathan H, Thuluvath PJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008;14:512-525.
  • 37
    Sgourakis G, Radtke A, Fouzas I, Mylona S, Goumas K, Gockel I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009;22:892-905.